Vascular Diseases Clinical Trial
Official title:
Study of the Effects of Bioflavonoids on Venous Wall Remodeling in Patients With Varicose Veins of the Lower Extremities
The study is aimed at assessing the dynamics of changes in biochemical markers of venous wall remodeling (type 1 plasminogen activation inhibitor (PAI-1), fibronectin (fibronectin, FN), vimentin (vimentin, VM), von Willebrand factor (vWF), PECAM-1 (CD31) ) in patients with C2s-C3s varicose veins compared with healthy volunteers while taking Venarus® (diosmin in combination with hesperidin).
The study will include 80 patients with varicose veins of the lower extremities, CEAP (CEAP classification stands for Clinical (C), Etiological (E), Anatomical (A), and Pathophysiological (P)) clinical class C2s-C3s and 20 healthy volunteers of similar age, gender, and ethnicity (100 patients altogether). The study participants will be divided into five groups: Group A: 20 patients with varicose veins who will be treated conservatively - receive the drug "Venarus®" (diosmin in combination with hesperidin) at a dosage of 1000 mg once daily for 6 months; Group B: 20 patients with varicose veins C2s-C3s who are not prescribed conservative therapy with venoactive drugs and will not undergo invasive treatment; Group C: 20 patients with varicose veins who will undergo invasive treatment (endovenous laser ablation with miniphlebectomy), followed by Venarus at a dosage of 1000 mg once daily for 6 months; Group D: 20 patients with varicose veins who will undergo invasive treatment (endovenous laser ablation with miniphlebectomy), after which no venoactive drugs will be prescribed. Group E: 20 healthy volunteers without clinical and ultrasound signs of varicose veins. All subjects in groups A, B, C, and D will receive elastic compression. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05971407 -
The Effect of Chronic Remote Ischaemic Preconditioning on Blood Pressure in Older Adults
|
N/A | |
Enrolling by invitation |
NCT03683186 -
A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension
|
Phase 3 | |
Recruiting |
NCT04390672 -
Multivessel TALENT
|
N/A | |
Recruiting |
NCT04584632 -
The Efemoral Vascular Scaffold System (EVSS) for the Treatment of Patients With Symptomatic Peripheral Vascular Disease From Stenosis or Occlusion of the Femoropopliteal Artery
|
N/A | |
Completed |
NCT01915368 -
Determining Optimal Post-Stroke Exercise (DOSE)
|
N/A | |
Completed |
NCT01684826 -
X-ray Dose Reduction Study for Cardiac Angiography and Intervention
|
N/A | |
Completed |
NCT01417910 -
Predictors of Post Operative Outcome in Peripheral Vascular Surgical Patients
|
N/A | |
Terminated |
NCT00935766 -
Effect of Fish Oil (Omega-3 Fatty Acids) on Arteries
|
Phase 3 | |
Unknown status |
NCT01748383 -
The Long-term and Short-term Efficacy and Safety of Transplantation Autologous Bone Marrow Cells (BMCs) in Patients With the First STEMI (ST Segment Elevation Myocardial Infarction)
|
Phase 2 | |
Recruiting |
NCT05907564 -
Aventus Thrombectomy System Pulmonary Embolism Clinical Study
|
N/A | |
Recruiting |
NCT03732612 -
Inflammation in Vascular Disease
|
||
Completed |
NCT00000614 -
Prevention of Recurrent Venous Thromboembolism (PREVENT)
|
Phase 3 | |
Completed |
NCT00000539 -
Arterial Disease Multifactorial Intervention Trial (ADMIT)
|
Phase 3 | |
Completed |
NCT00000479 -
Women's Health Study (WHS): A Randomized Trial of Low-dose Aspirin and Vitamin E in the Primary Prevention of Cardiovascular Disease and Cancer
|
Phase 3 | |
Completed |
NCT00000530 -
Raynaud's Treatment Study (RTS)
|
Phase 3 | |
Completed |
NCT00000474 -
Prevention and Treatment of Hypertension Study (PATHS)
|
Phase 3 | |
Completed |
NCT00000528 -
Trials of Hypertension Prevention (TOHP)
|
Phase 3 | |
Completed |
NCT00000509 -
Potassium and Sodium to Control Blood Pressure in Hypertensives
|
Phase 3 | |
Completed |
NCT00000501 -
Hypertension Prevention Trial (HPT) Feasibility Study
|
Phase 2 | |
Completed |
NCT00000499 -
Systolic Hypertension in the Elderly Program (SHEP) (Pilot Study)
|
Phase 2 |